Dr Mehul Lamba – Gastroenterologist & Endoscopy Specialist in Christchurch

After completing my core specialist training in New Zealand, I dedicated three years to high-volume international fellowships to bring world-class techniques back to the Canterbury region:

• Interventional Gastroenterology (2 years): Advanced luminal and pancreatobiliary training at the Royal Brisbane and Women’s Hospital, Australia.

• Therapeutic Endoscopy (1 year): Further specialist training at the world-renowned St. Michael’s Hospital in Toronto, Canada.

• Accredited Bowel Cancer screening Endoscopist

• High quality gastroscopy and colonoscopy

• Advanced interventional endoscopy including ERCP & EUS

• Endoscopic management of pre-cancerous lesions

• High quality Gastroscopy & Colonoscopy

• Bowel cancer screening

• Detection and endoscopic treatment of polyps and early cancer

• Gastro Oesophageal Reflux Disease (GORD, heartburn)

• Inflammatory Bowel Disease - Crohn`s Disease and Ulcerative colitis

• Coeliac Disease

• Irritable Bowel Syndrome

• Barrett`s Oesohpagus

• Liver disease

• Motility disorders

• Consultant Gastroenterologist & Interventional Endoscopist Christchurch Public hospital

• Clinical Senior Lecturer, University of Otago

• Executive Member, New Zealand Society of Gastroenterology

• Member, Gastroenterological Society of Australia

• Member, American Society for Gastrointestinal Endoscopy

1. Timing of Elective Endoscopic Procedures in Patients With Recent SARS-CoV-2 Infection

2. Establishment of standards for the referral of large nonpedunculated colorectal polyps: an international expert consensus using a modified Delphi process

3. Post-colonoscopy cancer rate at a tertiary referral hospital in Australia: A data linkage analysis.

4. Clinical utility of purgative bowel preparation before capsule endoscopy: a multicenter, blinded, randomized controlled trial.

5. Clinicopathological correlates of dysplastic sessile serrated lesion: a prospective cohort study with a high detection rate.

6. GESA Statement on the timing of elective endoscopic procedures in patients with recent COVID-19 infection.

7. Post-Endoscopy Upper Gastrointestinal Cancer Rate in a Tertiary Referral Centre: An Australian Data Linkage Analysis

8. Feasibility of resection and plication “RAP” technique for management of medically refractory GERD in patients with altered gastric anatomy.

9. Immunoglobulin G in non-alcoholic steatohepatitis predicts clinical outcome: A prospective multi-centre cohort study.

10. Trends in Incidence of Autoimmune Liver Diseases and Increasing Incidence of Autoimmune Hepatitis.

11. Associations Between Mutations in MSH6 and PMS2 and Risk of Surveillance-detected Colorectal Cancer

12. Risk of interval colorectal cancer in patients with Lynch Syndrome undergoing surveillance in New Zealand – results from the New Zealand Familial Gastrointestinal Cancer Service.

13. Predictors of non-attendance at outpatient endoscopy: a five-year multi-centre observational study from New Zealand.

14. Can colonoscopy at peripheral day hospitals meet internationally accepted quality and safety standards?

15. Editorial: inflammatory bowel disease risk reduction after migration - are early life events important?

16. Editorial: does disease extension lead to disease progression in proctitis?

17. HCC Surveillance in Patients with Advanced Fibrosis – Christchurch Experience

18. Contemporary Natural History of Patients with Severe and Moderate to Severe Aortic Regurgitation

19. Diagnosis of pulmonary embolism does not increase long-term risk of adverse clinical events.

20. Long-term outcomes in patients with pulmonary embolism: results from a longitudinal cohort study.